Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials-Reference-Cited by-同舟云学术

Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials

Published:2024-04 Issue:5 Volume:118 Page:1519-1530
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Lynch Connor,Korpics Mark C.,Katipally Rohan R.,Wu Tianming,Bestvina Christine M.,Pitroda Sean,Chmura Steven J.,Juloori Aditya

Funder

Merck & Co Inc

AstraZeneca

Bristol-Myers Squibb Co Summit

Publisher

Elsevier BV

Reference49 articles.

1. Phase II trial on SBRT for unresectable liver metastases: Long-term outcome and prognostic factors of survival after 5 years of follow-up;Scorsetti;Radiat Oncol,2018

2. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry;Mahadevan;Radiat Oncol,2018

3. The Dutch–Belgian registry of stereotactic body radiation therapy for liver metastases: Clinical outcomes of 515 patients and 668 metastases;Romero;Int J Radiat Oncol Biol Phys,2021

5. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline;Brahmer;J Clin Oncol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials;European Journal of Cancer;2024-09